Recon: AstraZeneca’s Voydeya for rare blood disorder wins FDA approval; FDA delays review of Biogen’s and Eisai’s injectable Leqembi
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States